Histone deacetylase (HDAC) are enzymes which remove acetyl groups from an N-acetyl lysine amino acid present on a histone, thus wrapping the DNA tightly by the histones. Histone deacetylase inhibitors (HDIs) are compounds which interfere with this function of histone deacetylase. HDIs display promising potential in oncology for applications such as diagnosis, cancer detection and prognosis. HDIs are emerging class of oncology therapeutics for the treatment of solid and hematological malignancies. Based on the classes, histone deacetylase are classified into class 1, class 2 and class 3 HDAC. HDAC inhibitors leads to accumulation of acetylated nuclear histones in both tumor and normal tissues, providing an alternate marker for the biological activity of HDAC inhibitors. Inhibition of HDAC also results in acetylation transcription factors such as GATA-1, p53 and estrogen receptor-alpha. HDIs are potent anti-proliferative agents with moderately little effect on normal tissues.
Get Sample Research Report: http://bit.ly/2ijrcHQ
Based on applications, histone deacetylase inhibitors are categorized into oncology, neurology and others diseases. Presently there are four approved HDI products in the market namely Vorinostat (Zolinza), Romidepsin (Istodax), Vidaza and Dacogen. Consequently, global biopharmaceutical companies are conducting research for its application in different indications.
North America leads the histone deacetylase inhibitors market with rapid acceptance of these products in this region. Globally, this market would be growing at a very rapid pace owing to a tremendous potential of this class of drugs in oncology therapy. Rising incidence of oncology and aging population would be the driving factors for this market.
Some of the key players in this market include Merck & Co., Inc., Celgene Corporation, Eisai Pharmaceuticals, Novartis, Acetylon Pharmaceuticals, Celleron Therapeutics, Envivo Pharmaceuticals and Pfizer, Inc. These companies are aiming to discover new products in this class, through prospective pipeline, collaborations and ventures.
Browse Full Research Report on Histone Histone Deacetylase Inhibitors Market:
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR Syndicated Research report covers a different sector – such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453
Browse market research blog:
This post has been seen 399 times.